BRUKINSA® Events

This is a promotional website intended for healthcare professionals in the UK and Ireland only.

Previous Events

11th October 2023 6:00PM BST – Virtual

BRUKINSA®▼ (zanubrutinib): A BTK inhibitor with a difference – Shaping the future of CLL treatment in Scotland 

This live virtual meeting brought together expert clinicians to discuss BRUKINSA, a next-generation BTK inhibitor, as a treatment option for patients with CLL.   Topics included clinical evidence supporting the use of BRUKINSA, patient case studies, the use of BRUKINSA in the NHS, and concluded with a panel-led Q&A session.  On-demand video content from this meeting […]

5th September 2023 6:00PM BST – Virtual

A BTK inhibitor with a difference – Shaping the future of CLL treatment

This meeting was a live-streaming event in which expert clinicians discussed BRUKINSA®▼, a next-generation BTK inhibitor, as a treatment option for patients with CLL. The agenda and speaker information can be found below. Topics included: Agenda Recordings BRUKINSA® : A next-generation BTK inhibitor – Dr Talha Munir BSH Guidelines: BRUKINSA® in CLL – Dr Renata […]

Read more

5th July 2023 6:00PM BST – Virtual

Real world experience treating WM and what’s next for CLL

This promotional meeting, sponsored by BeiGene, brought together a group of clinical experts to discuss their experience of treating patients with Waldenstrom’s Macroglobulinaemia using BRUKINSA®▼ (zanubrutinib), a next generation BTK inhibitor. This meeting involved sharing case studies and discussing the role of BRUKINSA in treatment pathways and hospital protocols. The second part of the meeting focused on the role […]

Read more

30th November 2022 6:30PM GMT – Virtual

The changing landscape of Waldenström’s Macroglobulinemia (WM) in Scotland

‘The changing landscape of Waldenström’s Macroglobulinemia (WM) in Scotland’ was a live virtual meeting. agenda Discussion topic Discussion Lead Welcome Dr Pam McKay The history and background of WM in Scotland Dr Pam McKay Current treatments: BSH guidelines Dr Dima El-Sharkawi An in-depth look at the ASPEN study Dr Shirley D’Sa and Dr Roger OwenDr […]

Read more

1st November 2022 3:00PM GMT – Virtual

The changing landscape of Waldenström’s Macroglobulinemia (WM)

The purpose of this meeting was to discuss the use of BRUKINSA®▼ (zanubrutinib), a next generation BTK inhibitor, in clinical practice and start the conversation about its place in the patient’s treatment pathway and in hospital protocols. The aim was to facilitate the exchange of best practice and expert opinion in order to benefit patients […]

Read more

Adverse events should be reported

United Kingdom (incl. Northern Ireland): Healthcare Professionals are asked to report any suspected adverse reactions via Yellow Card Scheme found at www.mhra.gov.uk/yellowcard.
Ireland: Healthcare Professionals are asked to report any suspected adverse reactions via HPRA.

All adverse events (UK and Ireland) should also be reported to BeiGene at [email protected]; (UK: 08009176799; Ireland: 1800812061).

For medical information, please contact: UK: 08004320266, Ireland: 1800946589 or email: [email protected]

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information.

September 2023 [0823-BRU-PRC-172]

Back to top

Brukinsa®▼ UK and Ireland healthcare professional website

This website contains information on BRUKINSA (zanubrutinib) and is intended for healthcare professionals in the UK and Ireland only.

To direct you to the most appropriate information, please confirm you are a UK or Ireland Healthcare Professional.

If you are not a UK or Ireland Healthcare Professional, you will be directed to the BRUKINSA Patient Information leaflet.

Are you a UK or Ireland Healthcare Professional?

0823-BRU-PRC-184 | September 2023

No, I am not